Invivyd, Inc.

Invivyd, Inc. is a biopharmaceutical company dedicated to the discovery, development, and commercialization of monoclonal antibody (mAb) therapies aimed at protecting individuals from serious viral infectious diseases. The company's mission involves leveraging state-of-the-art viral surveillance and predictive modeling alongside advanced antibody engineering to build a robust pipeline of product candidates. Invivyd is headquartered in New Haven, CT.

Invivyd's key product is PEMGARDA (pemivibart), a half-life extended investigational monoclonal antibody that has received Emergency Use Authorization (EUA) from the U.S. FDA for the pre-exposure prophylaxis (prevention) of COVID-19 in certain immunocompromised individuals. The company is actively developing next-generation antibody candidates, including VYD2311, which is in Phase III clinical trials for COVID-19, and VBY329, a pre-clinical stage monoclonal antibody targeting RSV infections and measles. These efforts are supported by its proprietary INVYMAB platform, designed for the rapid and serial generation of new mAbs to adapt to evolving viral threats.

In recent news, Invivyd announced progress in its REVOLUTION Program, including the advancement of VMS063, a novel measles monoclonal antibody candidate, in April 2026. The company also launched the “Antibodies for Any Body” campaign in partnership with World Champion Skier Lindsey Vonn in April 2026. For the full year 2025, Invivyd reported net product revenue for PEMGARDA of $53.4 million. William Duke, M.B.A., serves as the Chief Financial Officer and Principal Executive Officer, with Michael Mina, M.D., Ph.D., as Chief Medical Officer. The company anticipates top-line data for VYD2311 in mid-2026, reinforcing its commitment to addressing unmet needs in infectious disease prevention and treatment.